PWRM.OB - Discovered New Findings; STEM - Selling Shares to “Seaside” - StockHotTips.com
Power 3 Medical Products Inc. (PWRM.OB)
Recently, PWRM has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
PWRM has also developed a product called BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials. BC-SeraPro™ will be able to give a definate answer and they can catch it before, because they can see the elements of that where the test says positive but a mammogram says negative. There has been a 90% success rate through early studies for BC-SeraPro™.
Furthermore, PWRM recently has filed for 2 patent protection, one on Alzheimer’s disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer’s disease patients.
About Power 3 Medical Products Inc. (PWRM.OB)
PWRM, a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimers disease, and Parkinsons disease. Its product candidates include BC-SeraPro, a blood serum protein breast cancer test for the diagnosis of breast cancer and to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. PWRM products also comprise NuroPro, a blood serum protein neurodegenerative disease diagnostic screening test for disease diagnostics, such as neurological diseases of motor control, such as Parkinsons disease, ALS, and similarly disorders; ALS specific tests for ALS vs. ALS-like disorders; Alzheimers disease specific tests; and a Parkinsons disease specific test. PWRM has a joint venture agreement with NeoGenomics. PWRM was founded in 1992 and is based in The Woodlands, Texas.
For more information:http://www.Power3Medical.com
***************************************
StemCells Inc. (STEM)
| Last Trade: | 0.93 |
|---|---|
| Trade Time: | 3:12PM EDT |
| Change: |  0.01 (0.87%) |
| Prev Close: | 0.92 |
| Open: | 0.92 |
| Bid: | 0.93 x 600 |
| Ask: | 0.93 x 600 |
| Day’s Range: | 0.91 - 0.95 |
|---|---|
| 52wk Range: | 0.86 - 1.86 |
| Volume: | 379,745 |
| Avg Vol (3m): | 876,441 |
| Market Cap: | 111.06M |
STEM announced that it has entered into an agreement to sell seven million shares of its common stock to Seaside 88, LP (”Seaside”), a private investment partnership, at a price of $0.865 per share, which represents a 12.6% discount to the closing price per share of June 29. No warrants will be issued in this offering. The offering is expected to close on June 30, 2010, subject to customary closing conditions.
The shares are being offered under STEM’s effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). As part of the agreement, Seaside has agreed to purchase an additional five million shares of common stock 12 weeks after the initial closing, although STEM may elect not to sell the additional shares. In the event of a second closing, the purchase price will be calculated using the then-current trading price and no warrants would be issued.
STEM expects to receive net proceeds from the initial sale of seven million shares, after deducting offering expenses and fees, of approximately $5.7 million.
About StemCells Inc. (STEM)
STEM is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its cellular medicine programs, STEM is developing therapeutic products targeting diseases of the central nervous system and liver. STEMs’ lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. STEM also markets specialty cell culture products under the SC Proven®brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. STEM has exclusive rights to approximately 55 issued or allowed U.S. patents and over 200 granted or allowed non-U.S. patents.
*******************************************
Sign-Up For Free Hot Stock Alerts At http://stockhottips.com/signup
*******************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://stockhottips.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
